Silver Book Fact

The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but no optic, disc or visual field deterioration.

Kass M, Heuer D, Higginbotham E, Johnson C, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002; 120(6): 701-13. http://archopht.ama-assn.org/cgi/content/abstract/120/6/701

Reference

Title
The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
Publication
Archives of Ophthalmology
Publication Date
2002
Authors
Kass M, Heuer D, Higginbotham E, Johnson C, et al.
Volume & Issue
Volume 120, Issue 6
Pages
701-13
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Blood Pressure Control in Patients with Diabetes
    Tight blood pressure control in type 2 diabetes patients reduced progression of DR by 34% and risk of deterioration by 47% after 9 years.  
  • Prescription eye drops could delay or prevent half of glaucoma cases in African Americans.  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • Family risk of glaucoma
    “‘Five of my nine brothers and sisters had glaucoma,’ says 81-year-old Jean R. who for 20 years has depended on eye drops to decrease pressure inside her eyes. Jean is…  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.